ATR‐dependent ubiquitin‐specific protease 20 phosphorylation confers oxaliplatin and ferroptosis resistance
MedComm · 2023-12 · 4 (6)
DOI: 10.1002/mco2.463 ↗Kurz gefasst
Fachartikel in der Zeitschrift MedComm, online erschienen am 20.12.2023. Verfasst von Jianing Tang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Surgery Xiangya Hospital Central South University Changsha Hunan China. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Natural Science Foundation of Hunan Province.
Abstract (Originalsprache)
Oxaliplatin (OXA) resistance is a major clinic challenge in hepatocellular carcinoma (HCC). Ferroptosis is a kind of iron‐dependent cell death. Triggering ferroptosis is considered to restore sensitivity to chemotherapy. In the present study, we found that USP20 was overexpressed in OXA‐resistant HCC cells. High expression of USP20 in HCC was associated with poor prognosis. USP20 contributes OXA resistance and suppress ferroptosis in HCC. Pharmacological inhibition or knockdown of USP20 triggered ferroptosis and increased the sensitivity of HCC cells to OXA both in vitro and in vivo. Coimmunoprecipitation results revealed that the UCH domain of USP20 interacted with the N terminal of SLC7A11. USP20 stabilized SLC7A11 via removing K48‐linked polyubiquitination of SLC7A11 protein at K30 and K37. Most importantly, DNA damage‐induced ATR activation was required for Ser132 and Ser368 phosphorylation of USP20. USP20 phosphorylation at Ser132 and Ser368 enhanced its stability and thus conferred OXA and ferroptosis resistance of HCC cells. Our study reveals a previously undiscovered association between OXA and ferroptosis and provides new insight into mechanisms regarding how DNA damage therapies always lead to therapeutic resistance. Therefore, targeting USP20 may mitigate the development of drug resistance and promote ferroptosis of HCC in patients receiving chemotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Liver Surgery Xiangya Hospital Central South University Changsha Hunan China.
- National Clinical Research Center for Geriatric Disorders Xiangya Hospital Central South University Changsha Hunan China.
- Department of Pathology Xiangya Hospital Central South University Changsha Hunan China.
- Department of Oncology Institute of Medical Sciences National Clinical Research Center for Geriatric Disorders Xiangya Hospital Central South University Changsha Hunan China.
- Department of Pathology Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education) Xiangya Hospital Central South University Hunan China.
- Cancer Research Institute and School of Basic Medicine NHC Key Laboratory of Carcinogenesis (Central South University) Central South University Changsha Hunan China.
ORCID-Profile: Yongguang Tao
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Natural Science Foundation of Hunan Province
Zitieren
APA
Tang, J., Long, G., Xiao, D., Liu, S., Xiao, L., Zhou, L., & Tao, Y. (2023). ATR‐dependent ubiquitin‐specific protease 20 phosphorylation confers oxaliplatin and ferroptosis resistance. MedComm, 4(6). https://doi.org/10.1002/mco2.463
Vancouver
Tang J, Long G, Xiao D, Liu S, Xiao L, Zhou L, et al. ATR‐dependent ubiquitin‐specific protease 20 phosphorylation confers oxaliplatin and ferroptosis resistance. MedComm. 2023;4(6). doi:10.1002/mco2.463
BibTeX
@article{Tang2023,
author = {Tang, Jianing and Long, Guo and Xiao, Desheng and Liu, Shuang and Xiao, Liang and Zhou, Ledu and Tao, Yongguang},
title = {ATR‐dependent ubiquitin‐specific protease 20 phosphorylation confers oxaliplatin and ferroptosis resistance},
journal = {MedComm},
year = {2023},
volume = {4},
number = {6},
doi = {10.1002/mco2.463}
}
EUVIMED